{
  "author": "Noideawhatimdoing90",
  "the_new_excerpt": "So with all the medical mania happening recently, I did some DD on companies\nwith upcoming catalysts that could skyrocket the stock, and fell into Aurinia\npharmaceuticals. I will post link to the main article explaining in detail about\nit, but in short:\n\n-Aurinia Pharmaceuticals has one of the mostâ€¦",
  "original_created_utc": 1610037085,
  "localize": [
    {
      "locale": "zh",
      "the_new_excerpt": "æ‰€ä»¥ï¼Œåœ¨æœ€è¿‘æ‰€æœ‰çš„åŒ»å­¦ç‹‚çƒ­å‘ç”Ÿçš„æƒ…å†µä¸‹ï¼Œæˆ‘å¯¹å…¬å¸åšäº†ä¸€äº›DD\néšç€å³å°†åˆ°æ¥çš„å‚¬åŒ–å‰‚çš„å‡ºç°ï¼Œè‚¡ç¥¨å¯èƒ½ä¼šé£™å‡ï¼Œå¹¶è·Œå…¥é‡‘æ˜Ÿ\nåˆ¶è¯å…¬å¸ã€‚æˆ‘ä¼šè´´å‡ºä¸»è¦æ–‡ç« çš„é“¾æ¥ï¼Œè¯¦ç»†è§£é‡Š\nå®ƒï¼Œä½†ç®€è€Œè¨€ä¹‹ï¼š\n\n-é‡‘è‰²åˆ¶è¯æ‹¥æœ‰æœ€å¤šçš„â€¦ä¹‹ä¸€",
      "title": "é‡‘é»„è‰²åˆ¶è¯å…¬å¸(è¡Œæƒ…ä»£ç ï¼šAUPH)ä¸»è¦å‚¬åŒ–å‰‚1æœˆ22æ—¥"
    },
    {
      "locale": "zh-Hant",
      "the_new_excerpt": "æ‰€ä»¥ï¼Œåœ¨æœ€è¿‘æ‰€æœ‰çš„é†«å­¸ç‹‚ç†±ç™¼ç”Ÿçš„æƒ…æ³ä¸‹ï¼Œæˆ‘å°å…¬å¸åšäº†ä¸€äº›DD\néš¨ç€å³å°‡åˆ°ä¾†çš„å‚¬åŒ–åŠ‘çš„å‡ºç¾ï¼Œè‚¡ç¥¨å¯èƒ½æœƒé£†å‡ï¼Œä¸¦è·Œå…¥é‡‘æ˜Ÿ\nè£½è—¥å…¬å¸ã€‚æˆ‘æœƒè²¼å‡ºä¸»è¦æ–‡ç« çš„éˆæ¥ï¼Œè©³ç´°è§£é‡‹\nå®ƒï¼Œä½†ç°¡è€Œè¨€ä¹‹ï¼š\n\n-é‡‘è‰²è£½è—¥æ“æœ‰æœ€å¤šçš„â€¦ä¹‹ä¸€",
      "title": "é‡‘é»ƒè‰²è£½è—¥å…¬å¸(è¡Œæƒ…ä»£ç¢¼ï¼šAUPH)ä¸»è¦å‚¬åŒ–åŠ‘1æœˆ22æ—¥"
    }
  ],
  "title": "Aurinia pharmaceuticals (Ticker: AUPH) MAJOR catalyst January 22",
  "created_utc": 1610055028,
  "selftext_html": "<!-- SC_OFF --><div class=\"md\"><p>So with all the medical mania happening recently, I did some DD on companies with upcoming catalysts that could skyrocket the stock, and fell into Aurinia pharmaceuticals. I will post link to the main article explaining in detail about it, but in short:</p>\n\n<p>-Aurinia Pharmaceuticals has one of the most important milestones in its history in a few weeks.</p>\n\n<p>-Next January 22, 2021 is the PDUFA where the FDA will decide the approval of the candidate drug Voclosporin.</p>\n\n<p>-Voclosporin approval by the FDA is almost assured (estimated at 95% chance of approval) thanks to the very good phase III trial data presented last December 2019.</p>\n\n<p>-Estimates of the potential revenues that Voclosporin could generate worldwide once approved range from $1.5B to $3B per year.</p>\n\n<p>They also have around $400+ mill in cash on hand with great leadership. </p>\n\n<p>The only other completion they have in this field is Glaxosmithkline that currently produces an inferior product (just approved dec 17) and is currently trading at $38/share</p>\n\n<p>Right now AUPH is only $13 a share, and with the high probability of being approved in a couple weeks, I have a feeling this thing will ğŸš€ straight to the moon, and evidence of that is how it jumped to $21 last December when it released its phase 3 trial results. Currently all analysts have a buy rating at a PT average of $23.</p>\n\n<p>Do your own DD, but Iâ€™m in with $5k waiting for this home run</p>\n\n<p>Link: <a href=\"https://www.google.com/amp/s/seekingalpha.com/amp/article/4395615-aurinia-pharmaceuticals-offers-good-entry-opportunity-next-pdufa-for-voclosporin\">https://www.google.com/amp/s/seekingalpha.com/amp/article/4395615-aurinia-pharmaceuticals-offers-good-entry-opportunity-next-pdufa-for-voclosporin</a></p>\n</div><!-- SC_ON -->",
  "score": 70,
  "permalink": "/r/stocks/comments/ksgt1k/aurinia_pharmaceuticals_ticker_auph_major/",
  "subreddit": "stocks",
  "id": "ksgt1k",
  "is_self": true,
  "media": null,
  "is_video": false,
  "source_updated_at": 1610706379525
}